Monoclonal Antibodies: What the Diagnostic Neuroradiologist Needs to Know

0Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

Monoclonal antibodies have become increasingly popular as novel therapeutics against a variety of diseases due to their specificity, affinity, and serum stability. Due to the nearly infinite repertoire of monoclonal antibodies, their therapeutic use is rapidly expanding, revolutionizing disease course and management, and what is now considered experimental therapy may soon become approved practice. Therefore, it is important for radiologists, neuroradiologists, and neurologists to be aware of these drugs and their possible different imaging-related manifestations, including expected and adverse effects of these novel drugs. Herein, we review the most commonly used monoclonal antibody-targeted therapeutic agents, their mechanism of action, clinical applications, and major adverse events with a focus on neurologic and neurographic effects and discuss differential considerations, to assist in the diagnosis of these conditions.

Cite

CITATION STYLE

APA

Alsufayan, R., Hess, C., & Krings, T. (2023, December 1). Monoclonal Antibodies: What the Diagnostic Neuroradiologist Needs to Know. American Journal of Neuroradiology. American Society of Neuroradiology. https://doi.org/10.3174/ajnr.A7974

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free